Announcements Trials
Browse Landscape

Phase

Phase 3 6Phase 2 6Phase NA 5Phase 1/2 3Phase 2/3 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Neuroendocrine Tumors 7Thyroid Carcinoma, Anaplastic 3Thyroid Cancer, Papillary 3Neoplasms 3Multiple Endocrine Neoplasia Type 1 3Thyroid Neoplasms 2Somatostatinoma 2Ovarian Neoplasms 2Neoplasms by Site 2Neoplasms by Histologic Type 2Neoplasm Metastasis 2Multiple Myeloma 2Laryngeal Neoplasms 2Hematologic Neoplasms 2Glioma 2Gastroenteropancreatic Neuroendocrine Tumors 2Erdheim-Chester Disease 2Colorectal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Adrenal Gland Neoplasms 2Adenoma, Islet Cell 2Vipoma 1Thyroid cancer, Hurthle cell 1Pituitary Neoplasms 1Pheochromocytoma 1Parathyroid Neoplasms 1Paraganglioma 1Muscle Weakness 1Motor Activity 1Melanoma 1

Interventions

anlotinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Differentiated Thyroid Cancer × Endocrine × Clear all
NCT02586337 2019-05-21

Study of Anlotinib in Patients With Differentiated Thyroid Cancer(ALTER01032)

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 2/3 Unknown
113 enrolled
EndocrineHead & Neck

Differentiated Thyroid Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡